I notice that a new position at Acadia, first advertised last week, is the role of Senior Director, Strategic Product Planning, Rare Disease.
The successful candidate will “lead commercial strategy for Phase 3 pipeline products”.
Use of the plural is interesting, given that Acadia currently has just one Phase 3 rare disease program, namely ACP-101 for Hyperphagia in Prader-Willi syndrome.
ACP-2591 (NNZ-2591) in Rett syndrome and Fragile-X is not currently in active development and still needs to complete Phase 2 trials. Also, the assets Acadia licensed from Stoke Therapeutics are still at preclinical stage.
Acadia, page-819
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.32 |
Change
-0.025(0.20%) |
Mkt cap ! $1.570B | |||
| Open | High | Low | Value | Volume |
| $12.30 | $12.34 | $12.16 | $120.7K | 9.849K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 712 | $12.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.33 | 227 | 1 |
View Market Depth
| Last trade - 10.51am 05/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |